Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers

The Motherisk Program, Department of Pediatrics, Hospital for Sick Children, and Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.
Journal of Obstetrics and Gynaecology (Impact Factor: 0.55). 08/2011; 31(6):465-72. DOI: 10.3109/01443615.2011.579197
Source: PubMed


Studies of 1st trimester exposure to ACE inhibitors and angiotensin receptor blockers examining teratogenicity have shown conflicting results. We systematically reviewed the literature and performed a meta-analysis evaluating the risk of major malformations. For the meta-analysis, we included studies comparing 1st trimester exposure to no exposure, or to exposure to other antihypertensives. Additionally, we conducted a qualitative analysis of studies that did not meet the inclusion criteria for the meta-analysis. A significant risk ratio was found when the exposed group was compared with healthy controls but not when compared with other antihypertensives. The qualitative analysis did not demonstrate a specific pattern of major malformations. Our results suggest that 1st trimester exposure to ACE inhibitors and angiotensin receptor blockers is not associated with an elevated risk of major malformations compared with other antihypertensives. A 1st trimester exposure to antihypertensives in general may be associated with an elevated risk of major malformations.

26 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: A study by Li and coworkers demonstrates that antihypertensive-drug use and untreated hypertension in pregnancy increase the risk of congenital malformations. Supported by the results of meta-analysis, this study heralds a major shift in our understanding of the fetal risks of hypertension and the medications used to treat this condition.
    Nature Reviews Cardiology 11/2011; 9(1):7-8. DOI:10.1038/nrcardio.2011.179 · 9.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: QUESTION: One of my 35-year-old pregnant patients has been treated with enalapril for primary hypertension. She learned she was pregnant at 11 weeks' gestation. I read somewhere that angiotensin-converting enzyme (ACE) inhibitors can cause malformations. What advice do you give to Motherisk callers? ANSWER: Most published studies have failed to show an effect of ACE inhibitors on congenital malformations. A recent systematic review and meta-analysis conducted by Motherisk does not suggest increased fetal risk of malformations. However, ACE inhibitors should be avoided in late pregnancy, as they might cause renal failure and acalvaria in the baby.
    Canadian family physician Medecin de famille canadien 01/2012; 58(1):49-51. · 1.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Drugs that interfere with the renin-angiotensin system, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are widely used to manage hypertension and heart failure. Adequate functioning of the RAS is essential for normal fetal kidney development. The potential for ACEIs and ARBs to impair fetal and neonatal renal function if taken after the first trimester of pregnancy has been well documented. Although these drugs were not found to be teratogenic in animals, until recently little was known about the teratogenic effects of ACEIs and ARBs in humans when exposure was limited to the first trimester of pregnancy. New evidence from epidemiologic studies indicates that there may be an elevated teratogenic risk when these drugs are taken during the first trimester of pregnancy. However, this elevated risk does not appear to be specific to ACEIs and ARBs, but is instead related to maternal factors and diseases that typically coexist with hypertension in pregnancy, such as diabetes, advanced maternal age, and obesity. Women who become pregnant while being treated with an ACEI or ARB should be advised to avoid exposure to these drugs during the second and third trimesters of pregnancy by switching to a different class of antihypertensive drugs between weeks 8 and 10 after conception.
    Birth Defects Research Part A Clinical and Molecular Teratology 08/2012; 94(8):576-98. DOI:10.1002/bdra.23027 · 2.09 Impact Factor
Show more